MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling
Cancer Biotherapy and Radiopharmaceuticals · 01.04.2020 · 35 (3) · 223-232
DOI: 10.1089/cbr.2019.3031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, erschienen am 01.04.2020. Verfasst von Dankai Zhan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, China.
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Zitieren
APA
Zhan, D., Zhang, X., Li, J., Ding, X., Cui, Y., & Jia, J. (2020). MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling. Cancer Biotherapy and Radiopharmaceuticals, 35(3), 223-232. https://doi.org/10.1089/cbr.2019.3031
Vancouver
Zhan D, Zhang X, Li J, Ding X, Cui Y, Jia J. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling. Cancer Biotherapy and Radiopharmaceuticals. 2020;35(3):223-232. doi:10.1089/cbr.2019.3031
BibTeX
@article{Zhan2020,
author = {Zhan, Dankai and Zhang, Xinxin and Li, Jiahui and Ding, Xiaojiao and Cui, YiXuan and Jia, Jianguang},
title = {MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2020},
volume = {35},
number = {3},
pages = {223--232},
doi = {10.1089/cbr.2019.3031}
}
EUVIMED